Skip to main content

M&A could be the cure for the UK's threatened pharmaceutical industry

Updated
Published
Read Director, Karen Dawaf's piece in City AM here on how M&A activity could be the key to solving the pending national drug shortage, and prevent pharmaceutical providers from stockpiling.

Karen also discusses Arrowpoint Advisory's recent part in advising Inflexion Private Equity on its investment in European LifeCare Group.

Contact the team

Further news and insights

See all news and insights